Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.
Recent Content
- Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma
- NXC-201 Receives Orphan Drug Designation in European Union for Multiple Myeloma
- Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China
- From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma
- Acupuncture in Multiple Myeloma Peripheral Neuropathy: A Systematic Review
- Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
- Integrating p53-associated genes and infiltrating immune cell characterization as a prognostic biomarker in multiple myeloma
- The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)
- Tunisian Artemisia campestris L.: a potential therapeutic agent against myeloma – phytochemical and pharmacological insights
- International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma